How Preventive Biobanking Can Help Decode Long-Term Liver Health

Mumbai: Many patients discover liver damage at advanced stages, when treatment costs spiral. This is where preventive biobanking could be a solution. The liver does not complain; it compensates, adapts, and absorbs damage until it simply can’t anymore. And that’s what makes liver disease one of the most dangerous health threats of our time.

In India, liver disease accounts for around 2.6 lakh deaths annually, with certain conditions like fatty liver now affecting 1 in 3 urban Indians. What was once linked with alcohol is now linked to lifestyle factors: poor diet, obesity, diabetes and increasingly, hidden genetic predispositions.

Many patients discover liver damage at advanced stages, when reversal becomes difficult and treatment costs spiral. “Liver health today sits at the intersection of both lifestyle and genetics. While sedentary habits and processed foods increase conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), genetic factors influence who progresses quickly, who develops complications, and who remains asymptomatic,” says Dr Geetika Jassal, Medical Spokesperson, from Cryoviva Life Sciences.

As an example, she points out that two individuals with similar lifestyles may have completely different liver outcomes. This unpredictability is where current models of healthcare fall short. The system also identifies disease when it manifests, but very rarely predicts it before it begins. In a country battling with rising rates of obesity and diabetes, this gap is no longer acceptable.

Preventive biobanking is a future-facing approach to change this particular narrative. By collecting and analysing biological samples (blood markers, genetic data, and metabolic indicators) over time, biobanks usually create a longitudinal health map for individuals.

In India, early initiatives under ICMR and DBT are now beginning to explore well-structured repositories, but the real opportunity mainly lies in scaling them for preventive healthcare.

“For liver diseases, this also means identifying early biomarkers for damage, understanding genetic susceptibility, and improving risk stratification and enabling earlier identification of high-risk individuals,” informs Dr Jassal. It also shifts the focus from late-stage diagnosis to early, actionable insights.

The combination of biobanking along with precision medicine is emerging as a new frontier: precision prevention. Instead of general advice, individuals can also receive tailored interventions based on their genetic and metabolic profiles.

For an individual at high genetic risk of liver fibrosis, early dietary changes, well-targeted medication, and a continuous level of monitoring could prevent irreversible damage, according to Dr Jassal.

Globally, these kinds of approaches are already influencing clinical research, where biomarker-driven strategies are redefining pathways of treatments. India, with its diverse genetic pool, stands at a unique advantage to lead in this particular space – if the right infrastructure is built.

The future of liver health in India will not be defined by hospitals alone, but by how early we act. Investing in preventive biobanking, integrating genomics into routine care, and building awareness around the silent liver risk can transform outcomes since the real breakthrough is not in treating the liver disease but in ensuring it never reaches that stage.